ATE455847T1 - AUF TUMORE ZIELENDE ZELLEN, DIE DEN ßTUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDß (TRIAL) PRODUZIEREN - Google Patents

AUF TUMORE ZIELENDE ZELLEN, DIE DEN ßTUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDß (TRIAL) PRODUZIEREN

Info

Publication number
ATE455847T1
ATE455847T1 AT05764208T AT05764208T ATE455847T1 AT E455847 T1 ATE455847 T1 AT E455847T1 AT 05764208 T AT05764208 T AT 05764208T AT 05764208 T AT05764208 T AT 05764208T AT E455847 T1 ATE455847 T1 AT E455847T1
Authority
AT
Austria
Prior art keywords
trial
necrosis factor
ßtumor
ligandß
inducing
Prior art date
Application number
AT05764208T
Other languages
English (en)
Inventor
Alessandro GIANNI
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Application granted granted Critical
Publication of ATE455847T1 publication Critical patent/ATE455847T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05764208T 2004-07-29 2005-07-21 AUF TUMORE ZIELENDE ZELLEN, DIE DEN ßTUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDß (TRIAL) PRODUZIEREN ATE455847T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (de) 2004-07-29 2004-07-29 Tumor-ansteuernde Zellen, welche "tumor necrosis factor-related apoptosis inducing ligand" (TRAIL) exprimieren
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
ATE455847T1 true ATE455847T1 (de) 2010-02-15

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05764208T ATE455847T1 (de) 2004-07-29 2005-07-21 AUF TUMORE ZIELENDE ZELLEN, DIE DEN ßTUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDß (TRIAL) PRODUZIEREN

Country Status (25)

Country Link
US (1) US20070264231A1 (de)
EP (2) EP1621550A1 (de)
JP (1) JP5042826B2 (de)
KR (1) KR20070047757A (de)
CN (1) CN101076540B (de)
AT (1) ATE455847T1 (de)
AU (1) AU2005266543B2 (de)
BR (1) BRPI0513855A (de)
CA (1) CA2571426A1 (de)
DE (1) DE602005019050D1 (de)
DK (1) DK1771468T3 (de)
ES (1) ES2340400T3 (de)
HK (1) HK1110874A1 (de)
HR (1) HRP20100227T1 (de)
IL (1) IL180233A (de)
MX (1) MX2007001152A (de)
NO (1) NO20070956L (de)
NZ (1) NZ552223A (de)
PL (1) PL1771468T3 (de)
PT (1) PT1771468E (de)
RS (1) RS51381B (de)
RU (1) RU2390558C2 (de)
SI (1) SI1771468T1 (de)
WO (1) WO2006010558A1 (de)
ZA (1) ZA200701231B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070050911A (ko) * 2004-06-18 2007-05-16 제넨테크, 인크. Ａｐｏ２ｌ 수용체 작동제 및 ｎｋ 세포 활성화제의 사용방법
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
EP2811023B1 (de) * 2012-02-01 2018-10-24 Postech Academy-Industry Foundation Vektor zur gleichzeitigen expression von dodecamerischen pfad- und hsv-tk-selbstmordgenen sowie stammzellentherapeutikum damit
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
EP3209382B1 (de) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Kombinationsimmuntherapieansatz zur behandlung von krebs
ES2890859T3 (es) 2015-07-29 2022-01-24 Onk Therapeutics Ltd Células asesinas naturales modificadas y líneas de células asesinas naturales que tienen citotoxicidad aumentada
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US20220143089A1 (en) * 2019-03-21 2022-05-12 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
EP3712257A1 (de) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modifizierte natürliche killerzellen mit erhöhter resistenz gegen zelltod
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332435T3 (es) * 1997-06-04 2010-02-04 Oxford Biomedica (Uk) Limited Vector dirigido a tumores.
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
WO2002066044A2 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
SI1771468T1 (sl) 2010-07-30
HK1110874A1 (en) 2008-07-25
EP1771468B1 (de) 2010-01-20
WO2006010558A1 (en) 2006-02-02
ES2340400T3 (es) 2010-06-02
JP5042826B2 (ja) 2012-10-03
NZ552223A (en) 2009-01-31
RS51381B (en) 2011-02-28
PL1771468T3 (pl) 2010-07-30
KR20070047757A (ko) 2007-05-07
AU2005266543A1 (en) 2006-02-02
CN101076540B (zh) 2012-10-24
RU2390558C2 (ru) 2010-05-27
EP1771468A1 (de) 2007-04-11
NO20070956L (no) 2007-02-20
IL180233A (en) 2010-12-30
DE602005019050D1 (de) 2010-03-11
CA2571426A1 (en) 2006-02-02
AU2005266543B2 (en) 2012-02-02
RU2007107369A (ru) 2008-09-10
DK1771468T3 (da) 2010-05-25
MX2007001152A (es) 2007-04-18
BRPI0513855A (pt) 2008-05-20
JP2008507961A (ja) 2008-03-21
PT1771468E (pt) 2010-04-20
HRP20100227T1 (hr) 2010-07-31
ZA200701231B (en) 2008-08-27
CN101076540A (zh) 2007-11-21
IL180233A0 (en) 2007-07-04
US20070264231A1 (en) 2007-11-15
EP1621550A1 (de) 2006-02-01
WO2006010558A8 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
ATE455847T1 (de) AUF TUMORE ZIELENDE ZELLEN, DIE DEN ßTUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGANDß (TRIAL) PRODUZIEREN
CY1123192T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldν6)
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
EA202091486A1 (ru) Способы и композиции для поляризации макрофагов
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
UA111711C2 (uk) Засіб імунотерапії деяких видів пухлин, у тому числі раку шлунково-кишкового тракту і раку шлунка
ATE526987T1 (de) Dr5-antikörper und deren verwendung
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
ECSP088299A (es) Modulacion de la expresion del receptor de glucagon
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
EA201590986A1 (ru) Антитела к ceacam5 и их применения
SG170080A1 (en) Human monoclonal antibodies to o8e
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
EP2175879A4 (de) Behandlung von erkrankungen im zusammenhang mit prion-protein
WO2007090022A8 (en) Novel compounds for targeting endothelial cells, compositions containing the same and methods for their use
ZA200706338B (en) 1-H-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as FAK, KDR and TIE2 Kinase modulators for the treatment of cancer
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE602006016333D1 (de) Azaxanthonen zur behandlung von tumoren
MX2022007849A (es) Anticuerpos especificos contra la claudina 18.2 tumoral.
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
WO2019030757A8 (en) Chimeric antigen receptor for her2/neu and t-cells expressing same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1771468

Country of ref document: EP